| Market Capitalization (Millions $) |
15 |
| Shares
Outstanding (Millions) |
264 |
| Employees |
246 |
| Revenues (TTM) (Millions $) |
65 |
| Net Income (TTM) (Millions $) |
-170 |
| Cash Flow (TTM) (Millions $) |
-187 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Adaptimmune Therapeutics Plc is a biopharmaceutical company that specializes in the development of novel, personalized immunotherapies for the treatment of cancer. The company utilizes its T-cell receptor (TCR) platform to engineer T-cells to recognize and target specific cancer cells.
Adaptimmune's approach involves modifying a patient's own T-cells to express a specific TCR that can recognize cancer cells expressing a specific antigen. This personalized immunotherapy approach aims to enhance the body's immune response against cancer while minimizing damage to healthy cells.
The company has multiple clinical-stage programs targeting various types of solid tumors and hematologic malignancies. Their lead product candidate, ADP-A2M4, is currently being evaluated in Phase 2 trials for the treatment of multiple solid tumor types, including synovial sarcoma and head and neck cancer.
Adaptimmune also collaborates with pharmaceutical companies, including GlaxoSmithKline and Astellas Pharma, to further develop and commercialize its immunotherapy technologies. Overall, Adaptimmune Therapeutics Plc is focused on advancing the field of personalized cancer immunotherapy to provide more effective and durable treatments for patients.
Company Address: 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire 0
Company Phone Number: 1235 430000 Stock Exchange / Ticker: NASDAQ ADAP
|
0.16% 
81 %